We fund research that will cure, treat and prevent type 1 diabetes and its complications. Our global programme funds more than 500 active research projects around the world and supports more than 70 clinical trials at any one time. Internationally JDRF has funded £1.54 billion research to date and last year spent almost £72 million on research globally.
We focus on investing in research that will transform the lives of people with type 1 diabetes – improving treatments today until we find the cure.
This mission cannot be carried out in isolation, so we work with partner organisations to make sure we can change life with type 1 diabetes for the better as quickly as possible. But our most important partner is you – whether you help to fund the research, join a clinical trial or campaign for access to the new treatments that research delivers you are a vital member of our team.
Horizon 2020 underwrite guarantee update
UK Research and Innovation (UKRI) has been chosen to manage the underwrite delivery. The technical notice published Thursday 23 August 2018 provides more detail on the Horizon 2020 underwrite guarantee. This update is aimed at UK organisations, such as universities and businesses, who are in receipt of Horizon 2020 funding or who are bidding for such funding. The announcement includes a link to a government’s Q and A for full details.
Find out more
Discover how we're working to cure, treat and prevent type 1 diabetes
Finding a cure
Our cure research will give people with type 1 diabetes the ability to make their own insulin again.Find out more about our cure research
Type 1 diabetes treatment research focuses on finding new ways to keep people with type 1 as healthy as possible, until we find the cure.Find out more about our treatment research
Preventing type 1 diabetes
Preventing type 1 diabetes would mean lifting the burden of this condition from future generations.Find out more about our prevention research
Sign up for research updates
To hear about the latest progress in type 1 diabetes research, sign up for our e-newsletterSign up now